Related Experiment Videos
Postmenopausal hormone therapy: from monkey glands to transdermal patches
S R Davis1, I Dinatale, L Rivera-Woll
1Department of Medicine (CECS), Monash University, Victoria, Australia. Susan.Davis@med.monash.edu.au
The Journal of Endocrinology
|April 23, 2005
Summary
Hormonal therapy (HT) effectively manages menopausal vasomotor symptoms and prevents bone loss. However, HT is not recommended for cardiovascular disease or dementia prevention, and breast cancer risks vary by preparation.
Area of Science:
- Reproductive endocrinology
- Geriatric medicine
- Pharmacology
Background:
- The climacteric (menopause) is a natural physiological transition experienced by aging women.
- Increased life expectancy means more women live through menopause, desiring sustained health.
- Concerns exist regarding long-term health consequences of hormonal therapies (HTs) for menopausal symptom relief.
Purpose of the Study:
- To review the history of menopause and HT development.
- To summarize current evidence on HT benefits and risks.
- To inform clinical decisions regarding HT use.
Main Methods:
- Literature review of historical knowledge on menopause.
- Synthesis of evidence regarding hormonal therapy efficacy and safety.
- Analysis of risks and benefits for various HT preparations and indications.
Main Results:
- Hormonal therapy is appropriate for vasomotor symptoms and prevents bone loss/fractures.
- HT is not indicated for cardiovascular disease or dementia prevention.
- Estrogen-only therapy may carry minimal breast cancer risk; risks vary with progestin use.
- Insufficient data exists for long-term, low-dose, non-oral HT, tibolone, or SERMs regarding breast cancer and cardiovascular risks.
Conclusions:
- Hormonal therapy offers benefits for specific menopausal symptoms and bone health.
- Careful consideration of HT type, duration, and individual risk factors is crucial.
- Further research is needed for novel HTs and formulations to guide long-term recommendations.